27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Cognitive function was inversely related to all measures of disease pathology, indicating lower function at more severe levels of pathology. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Compared with individuals classed as normal, participants with preclinical Alzheimer's disease had an increased risk of death after adjusting for covariates (hazard ratio 6·2, 95% CI 1·1-35·0; p=0·040). 2 key findings →
Participants: 311 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study examined the temporal trends in the incidence rates of HIV dementia, cryptococcal meningitis, toxoplasmosis, progressive multifocal leukoencephalopathy, and CNS lymphoma from January 1990 to December 1998 in the Multicenter AIDS Cohort Study. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In a large community-based sample of middle-aged adults, BI predicted an increased risk of stroke and dementia independent of vascular risk factors. 5 key findings →
Participants: 1,694 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There are specific high-risk preexisting comorbidities for COVID-19 hospitalization and related deaths in community-based older men and women. 3 key findings →
Participants: 19 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Midlife hypertension is associated with later development of cognitive impairment, vascular dementia (VsD), and possibly Alzheimer's disease (AD). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During a mean follow-up of 3.6 years, 138 persons developed AD. 5 key findings →
Design: cohort study Participants: 138 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Prior work has suggested that obesity and overweight as measured by body mass index (BMI) increases risk of dementia. 4 key findings →
Participants: 10,136 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Key message Extensive variation was observed in conversion rates due to the population sampled, diagnostic criteria, and duration, and because many studies did not account for loss to follow-up. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cardiovascular autonomic dysfunction, REM sleep behavior disorder, color discrimination ability, and gait dysfunction strongly predict development of dementia in Parkinson disease. 1 key finding →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study included 33 858 patients in the GLP-1RA vs other GLD cohort (mean age, 65 years; 53.1% female), 34 185 patients in the SGLT2i vs other GLD cohort (mean age, 65.8 years; 49.3% female), and 24 117 patients in the GLP-1RA vs SGLT2i cohort (mean age, 63.8 years; 51.7% female). 5 key findings →
Participants: 33 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From 2520 records screened, 16 population-based studies were included and 12 contributed to meta-analyses. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest a higher prevalence of Alzheimer’s disease dementia in older individuals and a lower prevalence of preclinical Alzheimer’s disease in younger groups than previously estimated 2 . 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This meta-analysis included 21 studies involving 35,449 participants. 5 key findings →
Design: meta-analysis Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
NEFL (hazard ratio [HR] [95% confidence intervals (CIs)]: 1.54 [1.29, 1.84]) and RPS6KB1 (HR [95% CI]: 1.33 [1.16, 1.52]) were robustly associated with incident all-cause dementia; MMP12 (HR [95% CI]: 2.06 [1.41, 2.99]) was associated with vascular dementia in ELSA, after correcting for multiple testing. 3 key findings →
Design: longitudinal study Participants: 3,249 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As randomised trials are not always feasible or practical, observational studies remain crucial for addressing many causal questions in the dementia prevention field. 1 key finding →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The ACE is a brief and reliable bedside instrument for early detection of dementia, and offers a simple objective index to differentiate AD and FTD in mildly demented patients. 2 key findings →
Participants: 115 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Considering predementia stages, the number of persons with AD is much larger than conveyed in available literature. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Women who underwent either unilateral or bilateral oophorectomy before the onset of menopause had an increased risk of cognitive impairment or dementia compared to referent women (hazard ratio [HR] = 1.46; 95% CI 1.13 to 1.90; adjusted for education, type of interview, and history of depression). 2 key findings →
Participants: 813 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Participants were most likely to develop depression, apathy, or anxiety, and least likely to develop elation or disinhibition. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Contrary to previous reports, head trauma was not a risk factor for AD, and smoking did not protect against AD. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our prognostic index, which used 6 risk factors known at discharge and a simple additive point system to stratify medical patients 70 years or older according to 1-year mortality after hospitalization, had good discrimination and calibration and generalized well in an independent sample of patients at a different site. 2 key findings →
Participants: 1,495 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Twenty-two percent of the participants aged 75 years or older had MCI. 2 key findings →
Participants: 927 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These data demonstrate that YKL-40, a putative indicator of neuroinflammation, is elevated in AD and, together with Aβ42, has potential prognostic utility as a biomarker for preclinical AD. 3 key findings →
Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Dramatic increases in the numbers of "oldest old" (aged 85 years and older) across all racial and ethnic groups will also significantly affect the numbers of people living with AD. 1 key finding →
Participants: 200,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →